Cytokinetics(US:CYTK) Globenewswireยท2025-10-31 11:30Core Insights - Cytokinetics is set to present significant findings related to Aficamten at two major scientific sessions in November 2025, focusing on its effects in patients with obstructive hypertrophic cardiomyopathy (HCM) [1][4][7] Group 1: Upcoming Presentations - Three Late Breaking Science presentations on MAPLE-HCM will be featured at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions [1][4] - Presentations will include topics such as the impact of Aficamten versus Metoprolol on patient-reported health status and long-term outcomes in obstructive HCM [2][3][4] Group 2: Presentation Details - The first presentation will be by Michael E. Nassif, M.D., discussing the effect of Aficamten on patient-reported health status on November 7, 2025 [2] - Another key presentation by Andrew Wang, M.D., will analyze clinical responses to Aficamten compared to Metoprolol on November 8, 2025 [4] - Additional presentations will cover various aspects of Aficamten's efficacy and safety in different patient demographics and conditions [5][6] Group 3: Company Overview - Cytokinetics is a biopharmaceutical company specializing in cardiovascular treatments, with a focus on developing Aficamten, a cardiac myosin inhibitor, for obstructive HCM [7] - The company is preparing for potential regulatory approvals and commercialization of Aficamten following positive results from pivotal clinical trials [7]